Business Context and Reporting Period
This Form 8-K is a current report filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on April 25, 2016. The filing discloses the appointment of a new Chief Executive Officer and details the associated compensatory arrangements.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive personnel changes and compensation terms.
Material Changes
The primary material change reported is the appointment of William (Bill) Welch as Chief Executive Officer and principal executive officer, effective April 25, 2016.
Management Commentary and Compensation
- Executive Appointment: William Welch was appointed CEO. He previously served as President and CEO of Sequenom, Inc. (2014-2015) and held senior roles at Monogram Biosciences, La Jolla Pharmaceuticals, and Abbott Laboratories.
- Compensation Package:
- Annual base salary: $475,000.
- Annual target bonus: 50% of base compensation.
- Stock options: Grant of options to purchase up to 750,000 shares of common stock.
- Vesting schedule: 25% vests on the one-year anniversary of the grant date; the remainder vests monthly over 36 months beginning the first month after the one-year anniversary.
- Employment Agreement: A formal employment agreement is intended to be entered into within thirty days of the appointment.
Investor Verification Checklist
- Verify the execution of the formal employment agreement within the stated thirty-day window.
- Confirm the specific grant date for the 750,000 stock options to calculate the precise vesting schedule.
- Review the attached press release (Exhibit 99.1) for additional strategic context regarding the leadership change.
- Check subsequent filings for any changes to the compensation structure or vesting terms.